SVA Sinovac Biotech Ltd. Stock Quote

SVA [NASD]

Index	-	P/E	38.51	EPS (ttm)	0.17	Insider Own	43.46%	Shs Outstand	98.90M	Perf Week	-2.71%
Market Cap	639.90M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	44.27M	Perf Month	-0.46%
Income	-	PEG	3.21	EPS next Q	-	Inst Own	33.94%	Short Float	0.42%	Perf Quarter	-12.33%
Sales	264.28M	P/S	2.42	EPS this Y	-	Inst Trans	-	Short Ratio	12.22	Perf Half Y	0.62%
Book/sh	3.10	P/B	2.09	EPS next Y	-	ROA	-	Target Price	6.00	Perf Year	-20.07%
Cash/sh	-	P/C	-	EPS next 5Y	12.00%	ROE	-	52W Range	5.73 - 8.75	Perf YTD	-6.77%
Dividend	-	P/FCF	-	EPS past 5Y	-24.20%	ROI	-	52W High	-26.06%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	12.91%	ATR	0.18
Employees	910	Current Ratio	-	Sales Q/Q	79.40%	Oper. Margin	-	RSI (14)	46.31	Volatility	2.69% 2.41%
Optionable	No	Debt/Eq	-	EPS Q/Q	43.20%	Profit Margin	-	Rel Volume	-	Prev Close	6.47
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	15.38K	Price	6.47
Recom	3.00	SMA20	-0.45%	SMA50	-2.56%	SMA200	-10.61%	Volume	0	Change	0.00%

Feb-24-21 10:54AM	Brazil's SP state willing to supply 30 mln new COVID shots to federal govt Reuters
Feb-23-21 04:31AM	Thailand to start first coronavirus vaccinations this week Reuters
Feb-22-21 04:05PM	Sinovac Amends Shareholder Rights Plan Business Wire
09:04AM	UPDATE 1-Thailand allows emergency use of Sinovac's COVID-19 vaccine Reuters
Feb-19-21 09:25AM	Turkey to procure 105 mln doses of COVID-19 vaccines by end-April -Sabah Reuters
Feb-18-21 05:43PM	Asian Stocks Down, Weighed Down by Higher Bond Yields, Disappointing U.S. Data Investing.com
Feb-17-21 06:43PM	Under pressure, Brazil health minister promises more COVID vaccine shots Reuters
Feb-10-21 12:55PM	UPDATE 1-Minister says "absolutely calm" as Ukraine probes COVID-19 vaccine deal Reuters
Feb-09-21 04:30AM	Thailand Bets on Chinese Shots to Start Rollout By Month End Bloomberg
Feb-08-21 07:30AM	Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine Business Wire
Feb-07-21 05:13PM	Asian Stocks Up, Boosted by Yellen Push for U.S. Stimulus Measures Investing.com
Feb-06-21 04:03AM	UPDATE 3-China approves Sinovac Biotech COVID-19 vaccine for general public use Reuters
Feb-05-21 06:38PM	UPDATE 1-Sinovac says COVID-19 vaccine effective in preventing hospitalization, death Reuters
04:05PM	Sinovac Announces Phase III Results of Its COVID-19 Vaccine Business Wire

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also completed phase III clinical trials for varicella, pneumococcal polysaccharide, and Sabin inactivated polio vaccines. Further, it is developing rubella vaccine; Sabin-strain inactivated polio vaccine; Sars-coVv-2 (COVID-19) vaccine; and quadrivalent influenza vaccine. Sinovac Biotech Ltd. has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; Dynavax Technologies Corporation to develop a vaccine to prevent COVID-19; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. The company was founded in 1999 and is based in Beijing, the People's Republic of China.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience